NCT00836160View on ClinicalTrials.gov

Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

CompletedOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Cancer
Trial Locations (1)

Unknown

Research Site, Gueishan Township

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY